The Genetic Deletion of 6q21 and PRDM1 and Clinical Implications in Extranodal NK/T Cell Lymphoma, Nasal Type

Table 3

The clinical significance of the heterozygous deletion of 6q21 and PRDM1 and deletion of 6q21 and PRDM1.

		Percent	6q21			PRDM1			6q21/PRDM1
			Deletion	No deletion		Deletion	No deletion		Deletion	No deletion
Patients	43
Male	25	58.14	9	16	0.851	13	12	0.234	15	10	0.526
Female	18	41.86	7	11		6	12		9	9
Age (year)	43
60	32	74.42	13	19	0.441	13	19	0.435	18	14	0.924
60	11	25.58	3	8		6	5		6	5
Angiocentric infiltration	43
With	16	37.21	5	11	0.545	7	9	0.966	8	8	0.579
Without	27	62.79	11	16		12	15		16	11
Necrosis	43
With	34	79.07	13	21	0.793	16	18	0.473	20	14	0.452
Without	9	20.93	3	6		3	6		4	5
Site	43
Nasal	35	81.40	14	21	0.440	14	21	0.258	19	16	0.682
Extranasal	8	18.60	2	6		5	3		5	3
EBER	43
Positive	39	90.70	14	25	0.589	17	22	0.811	21	18	0.429
Negative	4	9.30	2	2		2	2		3	1
B symptom	40
With	20	50.00	5	15	0.055	6	14	0.059	9	11	0.115
Without	20	50.00	11	9		12	8		14	6
Ann arbor Stage	43
I/II	14	32.56	5	9	0.729	7	7	0.604	7	7	0.604
III/IV	29	67.44	12	17		12	17		17	12
Outcome	40
Alive	14	35.00	5	9	0.536	6	8	0.864	6	8	0.178
Dead	26	65.00	12	14		12	14		17	9